Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb;55(1):15-26.
doi: 10.1007/s13139-020-00674-3. Epub 2021 Jan 7.

Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis

Saurabh Arora  1 , Chandrasekhar Bal  1
Affiliations

Is There Any Need for Adjusting 131I Activity for the Treatment of High Turnover Graves' Disease Compared to Normal Turnover Patients? Results from a Retrospective Cohort Study Validated by Propensity Score Analysis

Saurabh Arora et al. Nucl Med Mol Imaging. 2021 Feb.

Abstract

Purpose: To compare 131I-therapy outcomes in high turnover and normal turnover Graves' disease patients and predict optimal first 131I activity for high turnover patients.

Methods: Retrospective cohort design (1:2) validated by propensity score analysis. Cohort 1, high turnover (2-h RAIU/24-h RAIU ≥ 1), n = 104, and cohort 2, normal turnover (ratio < 1), n = 208, patients were compared for post 131I outcome. The cure was defined as a combined euthyroid and stable hypothyroid state following 131I treatment. Logistic regression analysis was used for identifying prognostic factors. The propensity score was applied; 77 matched pairs (1:1 ratio) of high and normal turnover patients were selected as a validation set.

Results: First 131I cure rates of 28% in high turnover and 66% in normal turnover groups (p = 0.001) were noted. The therapy cycles (median, 2 vs. 1) and cumulative 131I activity (median, 15 vs. 7 mCi) were required to cure hyperthyroidism in cohort 1 and cohort 2, respectively. Age (> 44 years), higher grade of goitre, and 2-h RAIU (> 37%) were associated with 131I therapy failure. The high turnover patients needed a factor of 1.5-2 times more 131I activity to achieve a similar cure rate compared to the normal turnover patients. The first-dose cure rate was 31% vs. 60% by propensity score analysis (n = 154), no way different (28% vs.66%) from the whole group of 312 patients.

Conclusion: High turnover Graves' disease patients, if administered standard 131I activity, the outcomes shall be poor. To improve the success rate, 131I activity should be increased by 1.5 to 2 times in the high turnover patients.

Supplementary information: The online version contains supplementary material available at 10.1007/s13139-020-00674-3.

Keywords: Graves’ disease; High turnover; Normal turnover; Radioiodine therapy; Turnover.

PubMed Disclaimer

Conflict of interest statement

Conflict of InterestSaurabh Arora and Chandrasekhar Bal declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Flowchart showing a selection of patient cohorts, follow-up, and outcome in high and normal turnover groups. Cohort 1 of 104 Graves’ disease patients with high turnover and cohort 2 as the control group (1:2 age/sex-matched normal turnover GD) were selected
Fig. 2
Fig. 2
Time to event analysis (Kaplan Meier curves) (event: spontaneous conversion to hypothyroid state in euthyroid patients after completion of all RIT) showing the fate of euthyroid patients after completion of all RIT on long-term follow-up
See this image and copyright information in PMC

References

    1. Törring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine-a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81:2986–2993. - PubMed
    1. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS. Antithyroid drug regimen for treating Graves’ hyperthyroidism. Cochrane Database Syst Rev. 2010;2010:CD003420. - PMC - PubMed
    1. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1:129–135. - PubMed
    1. de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161:771–777. - PubMed
    1. Jaiswal AK, Bal C, Damle NA, Ballal S, Goswami R, Hari S, et al. Comparison of clinical outcome after a fixed-dose versus dosimetry-based radioiodine treatment of Graves’ disease: results of a randomized controlled trial in Indian population. Indian J Endocrinol Metab. 2014;18:648–654. - PMC - PubMed

LinkOut - more resources